HIV T-cell therapy - Fresenius

Drug Profile

HIV T-cell therapy - Fresenius

Latest Information Update: 18 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fresenius AG
  • Developer Fresenius SE & Co
  • Class Cell therapies; Gene therapies; Small interfering RNA
  • Mechanism of Action HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 14 Mar 2005 Data presented at the 12th Conference on Retroviruses and Opportunistic Infections (CROI-2005) have been added to the Viral Infections pharmacodynamics section
  • 31 Jan 2004 Phase-I/II clinical trials in HIV infections treatment in Germany (Infusion)
  • 19 Jan 2004 Preclinical trials in HIV infections treatment in Germany (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top